BRVE
Braveheart Bio, Inc.
Healthcare — Biotechnology
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
None
$21.41
+$1.21 (+5.98%)
Price History
52-Week Range
Sign in to add BRVE to a watchlist or set price alerts.
Fundamentals
| Market Cap | $1.77B |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-1.87 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 0.93 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | - |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $32.00 |
| 52-Week Low | $24.61 |
| 50-Day Avg | $29.11 |
| 200-Day Avg | $29.11 |
| Avg Volume | $1.42M |
| Volume | 723.9K |
Performance Analysis
NEUTRALBRVE presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($24.61), which could present a value opportunity.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 11, 2026 20:53 UTC
Back to Screener Export Report